Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10900120 | Cancer Letters | 2008 | 7 Pages |
Abstract
huHMFG-1 (AS1402) is a humanised IgG1 against MUC1, which exerts tumour cell killing through antibody-dependent cellular cytotoxicity (ADCC) mediated by natural killer (NK) cells. Here, we explored the capacity of invariant NKT (iNKT) cells, which are known to activate NK cells, and toll-like receptor (TLR) ligands which activate both iNKT and NK cells, to enhance huHMFG-1-ADCC. Addition of iNKT cells, as well as TLR2/6, 7, 8 and 9 agonists to PBMC improved the efficacy of huHMFG-1. These results suggest that transfer of ex vivo expanded iNKT cells or TLR agonist treatment may improve the efficacy of NK cell-mediated antibody-based tumour immunotherapies.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
MarÃa Moreno, Berber M. Mol, Silvia von Mensdorff-Pouilly, René H.M. Verheijen, B.Mary E. von Blomberg, Alfons J.M. van den Eertwegh, Rik J. Scheper, Hetty J. Bontkes,